A pre-revenue clinical developer funded by equity amid recurring research and trial costs
Intensity’s financial model remains pre-commercial: research and development and public-company costs consume cash, with no product revenue to fund them. It has relied on equity financing rather than internally generated cash, linking clinical activity, liquidity, and dilution.